statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Analyst Ratings For G1 Therapeutics

Latest Ratings for GTHX
 DateFirmActionFromTo Nov 2021JP MorganDowngradesNeutralUnderweight Nov 2021HC Wainwright & Co.MaintainsBuy Nov 2021Raymond JamesMaintainsOutperform
 View More Analyst...

What's Going On With G1 Therapeutics Stock?

According to a report, G1 Therapeutics has received and rejected multiple offers from TerSera Therapeutics. According to the report, one offer from TerSera is rumored to have a contingent value...

Evaluating G1 Therapeutics: Insights From 5 Financial Analysts

Biotech Innovations Paving the Way in Breast Cancer Fight

Biotech Innovations Paving the Way in Breast Cancer Fight Biotech Innovations Paving the Way in Breast Cancer Fight PR Newswire VANCOUVER, BC, April 11, 2024 FN Media Group Presents USA News Group...

G1 Therapeutics (NASDAQ:GTHX) vs. NLS Pharmaceutics (NASDAQ:NLSP) Head to Head Contrast

G1 Therapeutics (NASDAQ:GTHX - Get Free Report) and NLS Pharmaceutics (NASDAQ:NLSP - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two...

G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., April 04, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1's Chief Executive Officer Jack...

G1 Therapeutics (GTHX, $4.54) RSI Indicator left the overbought zone on April 01, 2024

This is a signal that GTHX's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

G1 Therapeutics, Inc. (NASDAQ:GTHX) Sees Significant Decline in Short Interest

G1 Therapeutics, Inc. (NASDAQ:GTHX - Get Free Report) saw a significant drop in short interest in March. As of March 15th, there was short interest totalling 2,690,000 shares, a drop of 7.6% from the...

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...

G1 Therapeutics (GTHX, $4.32) RSI Indicator left the overbought zone on March 28, 2024

G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.

Volume	492,235.00
52-Wk High	$6.14
52-Wk Low	$1.08

GTHX G1 Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals